Abundant kif21b is associated with accelerated progression in neurodegenerative diseases

Table 2 Quantification of kif21b expression in situ

Patient id	Age at death	Gender	Presenting symptom	Time to EDSS 6.0 (years)	Neuropathology assessment		Kif21b¹		Kif21b genotype
Patient id	Age at death	Gender	Presenting symptom	Time to EDSS 6.0 (years)	Braak stage	Amyloid	Neu-rons	Glia cells	Kif21b genotype
NDC2	49	F	NA	NA	0	ND	+	-	GA
NDC4	53	F			0	0	+/-	-	GA
NDC6	56	F			0	0	+/-	-	GG
NDC8	62	F			1	0	+/-	-	GA
NDC10	70	F			0	B	+	+	GA
NDC13	50	M			1	0	-	-	AA
NDC29	77	M			1	B	+/- / +	-	GG
NDC30	78	M			1	A	+/-	+/-	AA
NDC36	82	M			1	A	+/-	-	GG
MS4	50	F	Myelitis	7	ND	ND	-	-	GG
MS6	56	F	ND	4^*	ND	ND	+	+	GG
MS8	63	F	Optic neuritis	17	0	0	+	-	GA
MS10	70	F	Cerebrum	30	1	0	-	-	GG
MS23	56	M	Myelitis	2	ND	ND	-	-	AA
MS25	57	M	Myelitis	6	ND	ND	+/-	-	GG
MS40	74	M	Myelitis	8	3	0	-	-	AA
AD2	57	F	NA	NA	6	C	+	+/-	GA
AD4	57	F			6	C	+	-	GG
AD6	59	F			5	C	+/++	+/++	GA
AD8	63	F			5	C	+/-	-	GG
AD10	70	F			5	C	+	-	GA
AD13	42	M			6	C	+/-	+/-	AA
AD15	54	M			6	C	+	+/-	AA
AD20	58	M			4	C	++	++	GG
AD42	76	M			5	C	+	+/-	GA

In age-, gender- and genotyped matched MS and AD patients, kif21b protein expression was assessed. NA not applicable, ND not determined or documented.
¹scored as: - no positive cells, +/-1-2 positive cells per field, + maximum of ~30% of the cells positive, ++ ~60% of the cells positive, +++ ~80% positive cells and +++ (virtually) all cells positive.
^*time to EDSS 9.0.
Neuropathology assessment based on Braak criteria [12].

ISSN: 2051-5960